Anthera Pharmaceuticals Inc. buy klostergang
Start price
19.07.15
/
50%
€67.60
Target price
07.12.15
€120.00
Performance (%)
-45.04%
End price
07.12.15
€37.15
Summary
This prediction ended on 07.12.15 with a price of €37.15. Massive losses of -45.04% were the result for the BUY prediction by klostergang. klostergang has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Anthera Pharmaceuticals Inc. | - | - | - | - |
| iShares Core DAX® | 1.776% | 3.175% | 14.882% | 17.660% |
| iShares Nasdaq 100 | -1.037% | 1.869% | 35.463% | 52.324% |
| iShares Nikkei 225® | -0.335% | 3.857% | 14.485% | 11.459% |
| iShares S&P 500 | 0.854% | 2.567% | 31.105% | 47.441% |
Comments by klostergang for this prediction
In the thread Anthera Pharmaceuticals Inc. diskutieren
In Phase III der klinischen Entwicklung für die Behandlung von Krebsschmerzen
Anthera Pharmaceuticals (NASDAQ:ANTH)
- Develops cannabinoid prescription medicines to treat a wide range of therapeutic indications.
- Lead (licensing) product: Sativex. It is indicated as a treatment for symptom improvement in patients with spasticity due to MS.
- Q1 2015 revenue: $245 million.
- Sativex is currently in Phase III clinical development for the treatment of cancer pain. The company thinks that this will be the lead indication for the U.S. market.
(Vom Mitglied beendet)